

September 06, 2021

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol : PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
BSE Scrip Code: 531349

Re.: Press Release - Panacea Biotec supplies 1st shipment of the second component of Sputnik V vaccine produced in India

Dear Sir/Madam,

Panacea Biotec Ltd. is delighted to inform that the Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), and Panacea Biotec, one of India's leading vaccine and pharmaceutical manufacturers, has today announced supply of the 1st shipment out of 1 million doses of the second component (human adenovirus serotype 5) of the Russian Sputnik V coronavirus vaccine manufactured by the Company for sale in India.

A copy of the Press Release titled “**Panacea Biotec supplies 1st shipment of the second component of Sputnik V vaccine produced in India**” being issued to the media, etc. in this regard is enclosed for your kind reference and record please.

Kindly acknowledge the receipt.

Thanking you,

Sincerely yours,

for **Panacea Biotec Ltd.**



Vinod Goel
Group CFO and Head Legal
& Company Secretary

Encl. As Above

Panacea Biotec supplies 1st shipment of the second component of Sputnik V vaccine produced in India

New Delhi, September 6, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and Panacea Biotec Ltd. (Company), one of India’s leading vaccine and pharmaceutical manufacturers, announce supply of the 1st shipment out of 1 million doses of the second component (human adenovirus serotype 5) of the Russian Sputnik V coronavirus vaccine manufactured by Panacea Biotec for sale in India.

This is the first batch of the second component produced and supplied by the Company in India. Doses of the second component of Sputnik V have been manufactured at the Panacea Biotec’s state of the art vaccine manufacturing facility in Himachal Pradesh. The Company received necessary clearance from Central Drug Laboratories (CDL), Kasauli on August 31, 2021.

Full-scale production of Spuntik V started at Panacea Biotec’s facilities this summer. Facilities comply with GMP standards and are prequalified by WHO.

The batch will be distributed in India through a partner of RDIF and Panacea Biotec – Dr. Reddy’s Laboratories.


To date Sputnik V has been authorized in 70 countries with total population of over 4 billion people.

Dr. Rajesh Jain, Managing Director of Panacea Biotec, said:

“Panacea Biotec is pleased to have successfully produced and dispatched the first batch of Component II (Ad5) of Sputnik V vaccine. More batches are currently under production at our manufacturing facility in Himachal Pradesh.”

Sputnik V has a number of key advantages:

- *Efficacy of Sputnik V is 97.6% based on the analysis of data on the coronavirus infection rate among those in Russia vaccinated with both components of Sputnik V from December 5, 2020 to March 31, 2021;*
- *The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.*
- *Sputnik V has pioneered the use of heterogeneous boosting (two different vectors for the two shots in a course of vaccination among COVID vaccines).*



Panacea Biotec Ltd (CIN: L33117PB1984PLC022350)

Regd. Office : Ambala Chandigarh Higway, Lalru – 140501, Punjab

Correspondence/Corporate office : B-1 Extn../G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India

Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-4167 9070 Email: companysec@panaceabiotec.com

This approach provides for immunity with a longer duration than vaccines using the same delivery mechanism for both shots.

- *The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.*
- *There are no strong allergies caused by Sputnik V.*

Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF's management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling RUB 2.1 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia's GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than \$40 bn. Further information can be found at www.rdif.ru

For additional information contact:

Alexey Urazov

Russian Direct Investment Fund

Director for External Communications

Mobile: +7 915 312 76 65

[E-mail: Alexey.Urazov@rdif.ru](mailto:Alexey.Urazov@rdif.ru)

Andrew Leach / Maria Shiryayevskaya

Hudson Sandler

Tel: +44 (0) 20 7796 4133

